Trial Profile
A Randomized, Double-blind, Placebo-controlled Phase III Study, to Evaluate the Efficacy of Afatinib (BIBW2992) in Maintenance Therapy After Post- Operative Radio-chemotherapy in Squamous-cell Carcinoma of the Head and Neck: GORTEC 2010-02
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 29 Nov 2022
Price :
$35
*
At a glance
- Drugs Afatinib (Primary)
- Indications Head and neck cancer; Laryngeal cancer; Mouth neoplasm; Oropharyngeal cancer; Squamous cell cancer
- Focus Therapeutic Use
- Acronyms BIBW 2992 ORL
- 09 Nov 2022 Primary endpoint has not been met. (Disease Free Survival 2 years after the end of radiotherapy), as per Results published in the European Journal of Cancer
- 09 Nov 2022 Status has been changed to discontinued, as per Results published in the European Journal of Cancer
- 09 Nov 2022 Results published in the European Journal of Cancer